Cache Advisors LLC bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,143 shares of the company's stock, valued at approximately $392,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Arrowstreet Capital Limited Partnership boosted its position in Protagonist Therapeutics by 36.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company's stock valued at $8,340,000 after acquiring an additional 58,002 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Protagonist Therapeutics by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company's stock valued at $22,327,000 after acquiring an additional 12,906 shares during the period. Barclays PLC lifted its stake in Protagonist Therapeutics by 223.6% during the 3rd quarter. Barclays PLC now owns 126,995 shares of the company's stock valued at $5,714,000 after acquiring an additional 87,755 shares during the period. Louisiana State Employees Retirement System lifted its stake in Protagonist Therapeutics by 1.1% during the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock valued at $1,112,000 after acquiring an additional 300 shares during the period. Finally, Pacer Advisors Inc. lifted its stake in Protagonist Therapeutics by 8.2% during the 4th quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company's stock valued at $72,432,000 after acquiring an additional 142,376 shares during the period. Hedge funds and other institutional investors own 98.63% of the company's stock.
Analyst Upgrades and Downgrades
PTGX has been the subject of several recent research reports. BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Protagonist Therapeutics in a report on Monday, May 19th. Truist Financial lifted their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. Wedbush reissued an "outperform" rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a report on Friday, March 28th. Finally, The Goldman Sachs Group decreased their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $65.44.
View Our Latest Analysis on PTGX
Insider Activity
In other Protagonist Therapeutics news, Director William D. Waddill sold 4,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the transaction, the director now owns 13,130 shares of the company's stock, valued at $712,302.50. This represents a 23.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Asif Ali sold 24,903 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the completion of the transaction, the chief financial officer now directly owns 62,821 shares in the company, valued at $3,689,477.33. The trade was a 28.39% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 61,173 shares of company stock valued at $3,461,180. 4.90% of the stock is currently owned by insiders.
Protagonist Therapeutics Stock Performance
Shares of PTGX stock traded up $0.77 during trading hours on Tuesday, reaching $46.43. The company had a trading volume of 850,554 shares, compared to its average volume of 881,671. The stock has a fifty day moving average of $45.69 and a 200-day moving average of $42.53. The company has a market capitalization of $2.88 billion, a price-to-earnings ratio of 17.45 and a beta of 2.65. Protagonist Therapeutics, Inc. has a 12-month low of $27.00 and a 12-month high of $60.60.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.31. The firm had revenue of $28.32 million for the quarter, compared to analysts' expectations of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. On average, analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.
About Protagonist Therapeutics
(
Free Report)
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
See Also

Before you consider Protagonist Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.
While Protagonist Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.